Trial Profile
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Gilteritinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- Sponsors Astellas Pharma Global Development
- 15 Jun 2023 Results of a research from 17 cases assessing progression-free survival, overall-survival and side effect-survival analysis using data from a total of 7 centers, allowing the use of their data across Turkey between Apr 2020 and Oct 2021 presented at the 28th Congress of the European Haematology Association
- 12 Sep 2018 Status changed from recruiting to completed.
- 29 Jan 2018 New trial record